Nvidia will announce its earnings next week! The Blackwell cycle may continue to drive performance higher, with Wall Street collectively raising the target price.
Analysts generally believe that the current development of AI applications is still in the early stages, and the Blackwell cycle will continue to drive nvidia's performance higher. Credit Suisse expects that the new Blackwell product line will boost company revenue in the January quarter, with sales expected to be between $5 billion and $6 billion.
Huang Renxun's major announcement! Cooperating with Soft silver to build AI infrastructure in japan
On November 13, Nvidia CEO Huang Renxun announced at the Nvidia Japan Summit that they will partner with SoftBank to build AI infrastructure in Japan, including Japan's largest AI factory.
US stocks are on the move | nvidia rose more than 1.5%, Citigroup raised its target price to $170 and maintained a "buy" rating
Glonghui, November 14｜nvidia (NVDA.US) rose over 1.5%, reaching a high of $148.5, approaching its historical peak. In terms of news, Citigroup released a report stating that nvidia will announce its financial results for the quarter ending in October after the market closes on the 20th of this month. The bank predicts total sales and datacenter sales for the quarter will be $33 billion and $29 billion, respectively, considering the transition to Blackwell, and anticipates a non-GAAP earnings per share of $0.72, while the market generally expects $0.74. The bank expects that nvidia will see even larger "exceeding" results for the quarter ending in April next year.
Nvidia's stock price can rise another 26%, analysts say: "iPhone moment" is about to strike!
① The well-known Wall Street investment institution Melius Research states that investors should continue to hold nvidia, as the company's next-generation Blackwell GPU will become a watershed; ② Melius has raised nvidia's target stock price to $185, which represents an increase of about 26% from the current level.
Fabrinet Initiated With Equal Weight at Barclays on Valuation, Rising Competition
NVIDIA Invests in Genesis Therapeutics to Advance AI-Powered Drug Development